PROGESTIN/ESTRADIOL TRANSDERMAL GEL

600907 Provided is a transdermal system for contraceptive treatment of females comprising a carrier formulation including an amount of a progestin comprising 16-methylene-17a-acetoxy-19- norpregn-4-ene-3,20-dione sufficient to provide absorption of a daily dose of at least about. 300 micrograms of s...

Full description

Saved in:
Bibliographic Details
Main Authors CARRARA, DARIO NORBERTO, RAMON, GRENIER, ARNAUD, SITRUK-WARE, REGINE
Format Patent
LanguageEnglish
Published 29.11.2013
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:600907 Provided is a transdermal system for contraceptive treatment of females comprising a carrier formulation including an amount of a progestin comprising 16-methylene-17a-acetoxy-19- norpregn-4-ene-3,20-dione sufficient to provide absorption of a daily dose of at least about. 300 micrograms of said progestin to said female and to therefore provide mean plasma levels of at least about 500 pmol/L and estradiol sufficient to provide absorption of a daily dose of at least about 100micrograms of said estradiol to said female, whereby said transdermal system effectively blocks ovulation in the female and follicular development and rupture are prevented while irregular bleeding is minimized.
Bibliography:Application Number: NZ20100600907